Novo Nordisk (NYSE:NVO) and Anthropic announced a collaboration to apply Anthropic’s Claude AI models, including Claude Science, across Novo Nordisk’s research and development and software engineering activities.
Artelo Biosciences (NASDAQ:ARTL) reported nonclinical study results showing its ART27.13 compound produced approximately 20% body-weight loss over four weeks in obese mice, similar to semaglutide monotherapy.
IDEXX Laboratories (NASDAQ:IDXX) acquired CoVetAI, a provider of AI-powered ambient listening and clinical workflow software for veterinary practices worldwide.
Xenetic Biosciences (NASDAQ:XBIO) signed a definitive all-stock share exchange agreement to acquire all outstanding shares of Santersus AG, creating a combined biotechnology company focused on neutrophil extracellular trap (NET)-targeting therapeutics.
Bristol Myers Squibb (NYSE:BMY) declared a quarterly dividend of $0.63 per share on its $0.10 par value common stock following approval by its Board of Directors.
Viatris (NASDAQ:VTRS) received approval from Japan’s Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy.
Medtronic (NYSE:MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument, expanding the available tools for its Hugo robotic-assisted surgery system in the United States.
HeartSciences (NASDAQ:HSCS) reported fiscal first-quarter 2027 results with no meaningful revenue, a net loss of $3.2 million, and progress updates on its proposed business combination with Fortitude Mining Holdings.
Vera Therapeutics (NASDAQ:VERA) reported final Phase 3 ORIGIN 3 results showing TRUTAKNA (atacicept-vymj) stabilized kidney function and reduced disease progression over two years in adults with primary IgA nephropathy at risk of progression.
Connect Biopharma (NASDAQ:CNTB) reported preliminary topline Phase 2 results from the Seabreeze STAT Asthma study showing rademikibart improved lung function as an add-on treatment for acute asthma exacerbations with type 2 inflammation.
Rocket Pharmaceuticals (NASDAQ:RCKT) received alignment from the U.S. Food and Drug Administration on continued enrollment, dosing, and key design elements for its global Phase 2 pivotal trial of RP-A501 in patients with Danon disease.
Pulse Biosciences (NASDAQ:PLSE) completed enrollment in the PRECISE-BTN clinical study evaluating its nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules.
